SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis

BACKGROUND: The primary objective of this study was to analyze the cross-reactivity of antidrug antibodies to reference adalimumab (ADL) and SB5 (adalimumab biosimilar) in patients with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). METHODS: Sera from patients with IBD and RA with or...

Descripción completa

Detalles Bibliográficos
Autores principales: Goncalves, Joao, Myung, Gihyun, Park, MinJeong, Jeong, Deokyoon, Ghil, Jeehoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893927/
https://www.ncbi.nlm.nih.gov/pubmed/31839806
http://dx.doi.org/10.1177/1756284819891081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893927/
https://www.ncbi.nlm.nih.gov/pubmed/31839806
http://dx.doi.org/10.1177/1756284819891081

Ejemplares similares